{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:23:12Z","timestamp":1791894192490,"version":"4.3.4"},"reference-count":164,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by mutations in the GLA gene, resulting in a deficient activity of the enzyme \u03b1-galactosidase A (\u03b1-Gal A). This deficiency leads to the progressive accumulation of globotriaosylceramide (Gb3) and its deacylated form, globotriaosylsphingosine (Lyso-Gb3), in various tissues, contributing to a broad spectrum of clinical manifestations. Recent evidence highlights the crucial role of inflammation in the pathophysiology of FD, influencing disease progression and clinical outcomes. This review provides a comprehensive overview of the relationship between inflammation and FD, with a particular focus on the impact of inflammatory processes on disease progression and complications.<\/jats:p>","DOI":"10.3390\/ijms26157054","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T15:00:42Z","timestamp":1753196442000},"page":"7054","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Fabry Disease Beyond Storage: The Role of Inflammation in Disease Progression"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3335-1726","authenticated-orcid":false,"given":"Giuseppa","family":"Biddeci","sequence":"first","affiliation":[{"name":"Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9767-679X","authenticated-orcid":false,"given":"Gaetano","family":"Spinelli","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2470-7030","authenticated-orcid":false,"given":"Paolo","family":"Colomba","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Duro","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Giacalone","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8085-7538","authenticated-orcid":false,"given":"Francesco","family":"Di Blasi","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"476","DOI":"10.21037\/atm.2018.11.39","article-title":"Lysosomal storage disease overview","volume":"6","author":"Sun","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Coelho-Ribeiro, B., Silva, H.G., Sampaio-Marques, B., Fraga, A.G., Azevedo, O., Pedrosa, J., and Ludovico, P. (2024). Inflammation and Exosomes in Fabry Disease Pathogenesis. Cells, 13.","DOI":"10.3390\/cells13080654"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Thompson, S.E., Roy, A., Geberhiwot, T., Gehmlich, K., and Steeds, R.P. (2025). Fabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies. Biomedicines, 13.","DOI":"10.3390\/biomedicines13030624"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/B978-0-444-62702-5.00017-2","article-title":"Chapter 17\u2014Fabry disease","volume":"Volume 132","author":"Islam","year":"2015","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"jcs221739","DOI":"10.1242\/jcs.221739","article-title":"Lysosomal storage disorders\u2014Challenges, concepts and avenues for therapy: Beyond rare diseases","volume":"132","author":"Marques","year":"2019","journal-title":"J. Cell Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.amjms.2020.07.011","article-title":"When and How to Diagnose Fabry Disease in Clinical Pratice","volume":"360","author":"Michaud","year":"2020","journal-title":"Am. J. Med. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Tuttolomondo, A., Simonetta, I., Riolo, R., Todaro, F., Di Chiara, T., Miceli, S., and Pinto, A. (2021). Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221810088"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Simonetta, I., Tuttolomondo, A., Daidone, M., and Pinto, A. (2020). Biomarkers in Anderson\u2013Fabry Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218080"},{"key":"ref_9","first-page":"27","article-title":"Lysosomal storage diseases","volume":"2","author":"Ferreira","year":"2017","journal-title":"Transl. Sci. Rare Dis."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Amodio, F., Caiazza, M., Monda, E., Rubino, M., Capodicasa, L., Chiosi, F., Simonelli, V., Dongiglio, F., Fimiani, F., and Pepe, N. (2022). An Overview of Molecular Mechanisms in Fabry Disease. Biomolecules, 12.","DOI":"10.3390\/biom12101460"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40265-021-01486-1","article-title":"Fabry Disease: The Current Treatment Landscape","volume":"81","author":"Lenders","year":"2021","journal-title":"Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13023-025-03600-y","article-title":"Impact of enzyme replacement therapy and migalastat on disease progression in females with fabry disease","volume":"20","author":"Lenders","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Iacobucci, I., Hay Mele, B., Cozzolino, F., Monaco, V., Cimmaruta, C., Monti, M., Andreotti, G., and Monticelli, M. (2023). Enzyme Replacement Therapy for FABRY Disease: Possible Strategies to Improve Its Efficacy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054548"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jmcb\/mjt022","article-title":"The lysosome: From waste bag to potential therapeutic target","volume":"5","author":"Appelqvist","year":"2013","journal-title":"J. Mol. Cell Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"20423","DOI":"10.1074\/jbc.R110.134452","article-title":"Common and uncommon pathogenic cascades in lysosomal storage diseases","volume":"285","author":"Vitner","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/sj.cdd.4401727","article-title":"Immune surveillance of intracellular pathogens via autophagy","volume":"12","author":"Schmid","year":"2005","journal-title":"Cell Death Differ."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s00109-005-0014-4","article-title":"Autophagy in innate and adaptive immunity against intracellular pathogens","volume":"84","author":"Schmid","year":"2006","journal-title":"J. Mol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.0105-2896.2005.00310.x","article-title":"The lysosomal cysteine proteases in MHC class II antigen presentation","volume":"207","author":"Hsing","year":"2005","journal-title":"Immunol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00401-007-0296-4","article-title":"Immune system irregularities in lysosomal storage disorders","volume":"115","author":"Castaneda","year":"2008","journal-title":"Acta Neuropathol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Scerra, G., De Pasquale, V., Scarcella, M., Caporaso, M.G., Pavone, L.M., and D\u2019Agostino, M. (2022). Lysosomal positioning diseases: Beyond substrate storage. Open Biol., 12.","DOI":"10.1098\/rsob.220155"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.chembiol.2025.02.003","article-title":"Mechanisms and functions of lysosomal lipid homeostasis","volume":"32","author":"Ebner","year":"2025","journal-title":"Cell Chem. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/jimd.12558","article-title":"Aberrant autophagy in lysosomal storage disorders marked by a lysosomal SNARE protein shortage due to suppression of endocytosis","volume":"45","author":"Tanaka","year":"2022","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e12836","DOI":"10.15252\/emmm.202012836","article-title":"The rapidly evolving view of lysosomal storage diseases","volume":"13","author":"Parenti","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kurdi, H., Lavalle, L., Moon, J.C.C., and Hughes, D. (2024). Inflammation in Fabry disease: Stages, molecular pathways, and therapeutic implications. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1420067"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","article-title":"Contribution of inflammatory pathways to Fabry disease pathogenesis","volume":"122","author":"Rozenfeld","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s40292-020-00414-w","article-title":"The role of Immunity in Fabry Disease and Hypertension: A Review of a Novel Common Pathway","volume":"27","author":"Ferri","year":"2020","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ymgme.2019.05.009","article-title":"Tumor necrosis factor-\u03b1 links heat and inflammation with Fabry pain","volume":"127","author":"Urlaub","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"ref_28","first-page":"e1221","article-title":"Evaluation of Proinflammatory Prognostic Biomarkers for Fabry Cardiomyopathy with Enzyme Replacement Therapy","volume":"32","author":"Chen","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e009098","DOI":"10.1161\/JAHA.118.009098","article-title":"Elevated Inflammatory Plasma Biomarkers in Patients with Fabry Disease: A Critical Link to Heart Failure with Preserved Ejection Fraction","volume":"7","author":"Yogasundaram","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11897-024-00645-1","article-title":"Fabry Disease: Cardiac Implications and Molecular Mechanisms","volume":"21","author":"Weissman","year":"2024","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Biddeci, G., Spinelli, G., Colomba, P., Duro, G., Anania, M., Francofonte, D., and Di Blasi, F. (2025). Fabry Disease and Inflammation: Potential Role of p65 iso5, an Isoform of the NF-\u03baB Complex. Cells, 14.","DOI":"10.3390\/cells14030230"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Spinelli, G., Biddeci, G., Artale, A., Valentino, F., Tarantino, G., Gallo, G., Gianguzza, F., Conaldi, P.G., Corrao, S., and Gervasi, F. (2021). A new p65 isoform that bind the glucocorticoid hormone and is expressed in inflammation liver diseases and COVID-19. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-02119-z"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Yuan, Y., Zhao, Y., Li, F., Ling, C., Wu, Y., Ma, W., Wang, Z., Yuan, Y., Hao, H., and Zhang, W. (2024). Inflammatory cytokine expression in Fabry disease: Impact of disease phenotype and alterations under enzyme replacement therapy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1367252"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e2643","DOI":"10.6061\/clinics\/2021\/e2643","article-title":"Increased Serum Interleukin-6 and Tumor Necrosis Factor Alpha Levels in Fabry Disease: Correlation with Disease Burden","volume":"76","author":"Rosa","year":"2021","journal-title":"Clinics"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymgme.2013.02.003","article-title":"Fabry disease peripheral blood immune cells release inflammatory cytokines: Role of globotriaosylceramide","volume":"109","author":"Mucci","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.20517\/rdodj.2023.37","article-title":"The inflammatory pathogenetic pathways of Fabry nephropathy","volume":"3","author":"Feriozzi","year":"2024","journal-title":"Rare Dis. Orphan Drugs J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1007\/s11255-024-04042-4","article-title":"Fabry disease: A rare disorder calling for personalized medicine","volume":"56","author":"Lerario","year":"2024","journal-title":"Int. Urol. Nephrol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet. Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Azevedo, O., Gago, M.F., Miltenberger-Miltenyi, G., Sousa, N., and Cunha, D. (2020). Fabry Disease Therapy: State-of-the-Art and Current Challenges. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010206"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Capelli, I., Aiello, V., Gasperoni, L., Comai, G., Corradetti, V., Ravaioli, M., Biagini, E., Graziano, C., and La Manna, G. (2020). Kidney Transplant in Fabry Disease: A Revision of the Literature. Medicina, 56.","DOI":"10.3390\/medicina56060284"},{"key":"ref_44","first-page":"2","article-title":"Fabry disease in women: Beyond the role of \u201ccarriers\u201d","volume":"4","year":"2025","journal-title":"Rare Dis. Orphan Drugs J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Juchniewicz, P., Piotrowska, E., Kloska, A., Podlacha, M., Mantej, J., W\u0119grzyn, G., Tukaj, S., and Jak\u00f3bkiewicz-Banecka, J. (2021). Dosage Compensation in Females with X-Linked Metabolic Disorders. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094514"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Cammarata, G., Fatuzzo, P., Rodolico, M.S., Colomba, P., Sicurella, L., Iemolo, F., Zizzo, C., Alessandro, R., Bartolotta, C., and Duro, G. (2015). High variability of Fabry disease manifestations in an extended Italian family. BioMed Res. Int., 2015.","DOI":"10.1155\/2015\/504784"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"61415","DOI":"10.18632\/oncotarget.18250","article-title":"Inter-familial and intra-familial phenotypic variability in three Sicilian families with Anderson-Fabry disease","volume":"8","author":"Tuttolomondo","year":"2017","journal-title":"Oncotarget"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/TACG.S146022","article-title":"Multiple phenotypic domains of Fabry disease and their relevance for establishing genotype-phenotype correlations","volume":"12","author":"Oliveira","year":"2019","journal-title":"Appl. Clin. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13023-022-02215-x","article-title":"Expert opinion on the recognition, diagnosis and management of children and adults with Fabry disease: A multidisciplinary Turkey perspective","volume":"17","author":"Ezgu","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/gim.2016.55","article-title":"Is it Fabry disease?","volume":"18","author":"Schiffmann","year":"2016","journal-title":"Genet. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","article-title":"A systematic review on screening for Fabry disease: Prevalence of individuals with genetic variants of unknown significance","volume":"51","author":"Smid","year":"2014","journal-title":"J. Med. Genet."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijcard.2014.09.001","article-title":"Uncertain diagnosis of Fabry disease: Consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance","volume":"177","author":"Smid","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10897-013-9613-3","article-title":"Fabry disease practice guidelines: Recommendations of the National Society of Genetic Counselors","volume":"22","author":"Laney","year":"2013","journal-title":"J. Genet. Couns."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Jehn, U., Bayraktar, S., Pollmann, S., Van Marck, V., Weide, T., Pavenst\u00e4dt, H., Brand, E., and Lenders, M. (2021). \u03b1-Galactosidase a Deficiency in Fabry Disease Leads to Extensive Dysregulated Cellular Signaling Pathways in Human Podocytes. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111339"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.clinbiochem.2012.04.030","article-title":"Comparison between alpha-galactosidase A activity in blood samples collected on filter paper, leukocytes and plasma","volume":"45","author":"Daitx","year":"2012","journal-title":"Clin. Biochem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.33393\/gcnd.2017.698","article-title":"DBS assay in the diagnosis of Fabry disease","volume":"29","author":"Scalia","year":"2017","journal-title":"G. Di Tec. Nefrol. E Dial."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1096-7192(03)00136-7","article-title":"Fabry disease: D313Y is an \u03b1-galactosidase A sequence variant that causes pseudodeficient activity in plasma","volume":"80","author":"Froissart","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Izhar, R., Borriello, M., La Russa, A., Di Paola, R., De, A., Capasso, G., Ingrosso, D., Perna, A.F., and Simeoni, M. (2024). Fabry Disease in Women: Genetic Basis, Available Biomarkers, and Clinical Manifestations. Genes, 15.","DOI":"10.3390\/genes15010037"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Duro, G., Anania, M., Zizzo, C., Francofonte, D., Giacalone, I., D\u2019Errico, A., Marsana, E.M., and Colomba, P. (2024). Diagnosis of Fabry Disease Using Alpha-Galactosidase A Activity or LysoGb3 in Blood Fails to Identify Up to Two Thirds of Female Patients. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25105158"},{"key":"ref_61","first-page":"100952","article-title":"Distinctive accumulation of globotriaosylceramide and globotriaosylsphingosine in a mouse model of classic Fabry disease","volume":"34","author":"Taguchi","year":"2023","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2","DOI":"10.23876\/j.krcp.23.125","article-title":"Screening and diagnosis of Fabry disease in chronic kidney disease: The important role of globotriaosylsphingosine","volume":"43","author":"Shin","year":"2024","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Sueoka, H., Ichihara, J., Tsukimura, T., Togawa, T., and Sakuraba, H. (2015). Nano-LC-MS\/MS for Quantification of Lyso-Gb3 and Its Analogues Reveals a Useful Biomarker for Fabry Disease. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0127048"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2174\/092986713804806685","article-title":"A metabolomic study reveals novel plasma lyso-Gb3 analogs as Fabry disease biomarkers","volume":"20","author":"Dupont","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Ivanova, M.M., Changsila, E., Iaonou, C., and Goker-Alpan, O. (2019). Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0210617"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10545-010-9114-6","article-title":"A modified lipid composition in Fabry disease leads to an intracellular block of the detergent-resistant membrane-associated dipeptidyl peptidase IV","volume":"33","author":"Maalouf","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.cell.2010.03.006","article-title":"Inflammation 2010: New adventures of an old flame","volume":"140","author":"Medzhitov","year":"2010","journal-title":"Cell"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Oronsky, B., Caroen, S., and Reid, T. (2022). What Exactly Is Inflammation (and What Is It Not?). Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232314905"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Lawrence, T. (2009). The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb. Perspect. Biol., 1.","DOI":"10.1101\/cshperspect.a001651"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1301\/nr.2007.dec.S140-S146","article-title":"Inflammatory Mechanisms: The Molecular Basis of Inflammation and Disease","volume":"65","author":"Libby","year":"2007","journal-title":"Nutr. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1610136","DOI":"10.3389\/pore.2021.1610136","article-title":"Inflammation in Focus: The Beginning and the End","volume":"27","author":"Kiss","year":"2022","journal-title":"Pathol. Oncol. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"R119","DOI":"10.1093\/hmg\/ddy155","article-title":"The pathogenesis of lysosomal storage disorders: Beyond the engorgement of lysosomes to abnormal development and neuroinflammation","volume":"27","author":"Fiorenza","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.4110\/in.2018.18.e27","article-title":"Damage-Associated Molecular Patterns in Inflammatory Diseases","volume":"18","author":"Roh","year":"2018","journal-title":"Immune Netw."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12935-025-03771-5","article-title":"Lysosomes: Guardians and healers within cells- multifaceted perspective and outlook from injury repair to disease treatment","volume":"25","author":"Bi","year":"2025","journal-title":"Cancer Cell Int."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41419-020-03032-5","article-title":"Lysosomal quality control of cell fate: A novel therapeutic target for human diseases","volume":"11","author":"Zhu","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Di Mambro, T., Pellielo, G., Agyapong, E.D., Carinci, M., Chianese, D., Giorgi, C., Morciano, G., Patergnani, S., Pinton, P., and Rimessi, A. (2023). The Tricky Connection between Extracellular Vesicles and Mitochondria in Inflammatory-Related Diseases. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098181"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/01.ASN.0000121781.89599.16","article-title":"Signaling danger: Toll-like receptors and their potential roles in kidney disease","volume":"15","author":"Anders","year":"2004","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Wicherska-Paw\u0142owska, K., Wr\u00f3bel, T., and Rybka, J. (2021). Toll-Like Receptors (TLRs), NOD-Like Receptors (NLRs), and RIG-I-Like Receptors (RLRs) in Innate Immunity. TLRs, NLRs, and RLRs Ligands as Immunotherapeutic Agents for Hematopoietic Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222413397"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.immuni.2024.03.004","article-title":"Decoding Toll-like receptors: Recent insights and perspectives in innate immunity","volume":"57","author":"Kawai","year":"2024","journal-title":"Immunity"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s12276-021-00683-y","article-title":"Human kidney organoids reveal the role of glutathione in Fabry disease","volume":"53","author":"Kim","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1093\/hmg\/ddv291","article-title":"Lyso-Gb3 activates Notch1 in human podocytes","volume":"24","author":"Carpio","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Laffer, B., Lenders, M., Ehlers-Jeske, E., Heidenreich, K., Brand, E., and K\u00f6hl, J. (2024). Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1307558"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Pandey, M.K. (2023). Exploring Pro-Inflammatory Immunological Mediators: Unraveling the Mechanisms of Neuroinflammation in Lysosomal Storage Diseases. Biomedicines, 11.","DOI":"10.3390\/biomedicines11041067"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s10157-021-02058-z","article-title":"Pathology and pathogenic pathways in fabry nephropathy","volume":"25","author":"Feriozzi","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s10753-015-0214-1","article-title":"Elevated Endomyocardial Biopsy Macrophage-Related Markers in Intractable Myocardial Diseases","volume":"38","author":"Hayashi","year":"2015","journal-title":"Inflammation"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Ivanova, M.M., Dao, J., Friedman, A., Kasaci, N., and Goker-Alpan, O. (2025). Sex Differences in Circulating Inflammatory, Immune, and Tissue Growth Markers Associated with Fabry Disease-Related Cardiomyopathy. Cells, 14.","DOI":"10.3390\/cells14050322"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_88","first-page":"11","article-title":"Immune response and autoimmune diseases: A matter of sex","volume":"5","author":"Dupuis","year":"2019","journal-title":"Ital. J. Gender-Specif. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ymgme.2011.03.022","article-title":"Response of women with Fabry disease to enzyme replacement therapy: Comparison with men, using data from FOS--the Fabry Outcome Survey","volume":"103","author":"Hughes","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s13023-024-03503-4","article-title":"Impact of enzyme replacement therapy on clinical manifestations in females with Fabry disease","volume":"19","author":"Lenders","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10545-011-9400-y","article-title":"Fabry disease, enzyme replacement therapy and the significance of antibody responses","volume":"35","author":"Deegan","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41581-025-00938-1","article-title":"Endoplasmic reticulum stress as a driver and therapeutic target for kidney disease","volume":"21","author":"Byun","year":"2025","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"101169","DOI":"10.1016\/j.molmet.2021.101169","article-title":"A guide to understanding endoplasmic reticulum stress in metabolic disorders","volume":"47","author":"Lemmer","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_94","first-page":"100926","article-title":"\u03b1-Gal A missense variants associated with Fabry disease can lead to ER stress and induction of the unfolded protein response","volume":"33","author":"Consolato","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"107700","DOI":"10.1016\/j.ymgme.2023.107700","article-title":"c.376A>G, (p.Ser126Gly) Alpha-Galactosidase A mutation induces ER stress, unfolded protein response and reduced enzyme trafficking to lysosome: Possible relevance in the pathogenesis of late-onset forms of Fabry Disease","volume":"140","author":"Riillo","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1093\/hmg\/ddad073","article-title":"Elucidating the toxic effect and disease mechanisms associated with Lyso-Gb3 in Fabry disease","volume":"32","author":"Nikolaenko","year":"2023","journal-title":"Hum. Mol. Genet."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nri.2016.62","article-title":"The unfolded protein response in immunity and inflammation","volume":"16","author":"Grootjans","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.cell.2005.11.040","article-title":"Endoplasmic Reticulum Stress Activates Cleavage of CREBH to Induce a Systemic Inflammatory Response","volume":"124","author":"Zhang","year":"2006","journal-title":"Cell"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1161\/ATVBAHA.113.302744","article-title":"Globotriaosylceramide induces endothelial dysfunction in fabry disease","volume":"34","author":"Satoh","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Stepien, K.M., Roncaroli, F., Turton, N., Hendriksz, C.J., Roberts, M., Heaton, R.A., and Hargreaves, I. (2020). Mechanisms of Mitochondrial Dysfunction in Lysosomal Storage Disorders: A Review. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082596"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.molmed.2016.12.003","article-title":"Mitochondrial Dysfunction and Neurodegeneration in Lysosomal Storage Disorders","volume":"23","author":"Plotegher","year":"2017","journal-title":"Trends Mol. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.mito.2023.10.003","article-title":"Mitochondrial dysfunction and inflammasome activation in neurodegenerative diseases: Mechanisms and therapeutic implications","volume":"73","author":"Hamzeh","year":"2023","journal-title":"Mitochondrion"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12974-025-03363-0","article-title":"Mitochondrial DNA leakage: Underlying mechanisms and therapeutic implications in neurological disorders","volume":"22","author":"Zhang","year":"2025","journal-title":"J. Neuroinflamm."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Chen, Y., Ye, X., Escames, G., Lei, W., Zhang, X., Li, M., Jing, T., Yao, Y., Qiu, Z., and Wang, Z. (2023). The NLRP3 inflammasome: Contributions to inflammation-related diseases. Cell. Mol. Biol. Lett., 28.","DOI":"10.1186\/s11658-023-00462-9"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/jimd.12373","article-title":"Defective lysosomal storage in Fabry disease modifies mitochondrial structure, metabolism and turnover in renal epithelial cells","volume":"44","author":"Schumann","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","article-title":"Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells","volume":"95","author":"Shen","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cyto.2012.12.011","article-title":"Vascular Endothelial Growth Factor (VEGF-a) in Fabry disease: Association with cutaneous and systemic manifestations with vascular involvement","volume":"61","author":"Zampetti","year":"2013","journal-title":"Cytokine"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Namdar, M., Gebhard, C., Studiger, R., Shi, Y., Mocharla, P., Schmied, C., Brugada, P., L\u00fcscher, T.F., and Camici, G.G. (2012). Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease. PLoS ONE, 7.","DOI":"10.1371\/annotation\/7b2c04df-8592-4fb7-8608-3039db28b504"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2009.10.004","article-title":"Vasculopathy in patients with Fabry disease: Current controversies and research directions","volume":"99","author":"Rombach","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"ref_111","first-page":"899","article-title":"Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers","volume":"9","author":"Collins","year":"1995","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Pollmann, S., Scharnetzki, D., Manikowski, D., Lenders, M., and Brand, E. (2021). Endothelial Dysfunction in Fabry Disease Is Related to Glycocalyx Degradation. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.789142"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"key":"ref_114","first-page":"18","article-title":"Interpretation of GFR slope in untreated and treated adult Fabry patients","volume":"39","author":"Pisani","year":"2023","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc.-Eur. Ren. Assoc."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s12325-024-03041-2","article-title":"Effects of Current Therapies on Disease Progression in Fabry Disease: A Narrative Review for Better Patient Management in Clinical Practice","volume":"42","author":"Mignani","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000493469","article-title":"Glomerular Hyperfiltration: An Early Marker of Nephropathy in Fabry Disease","volume":"141","author":"Riccio","year":"2019","journal-title":"Nephron"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1016\/j.ekir.2019.05.401","article-title":"Sun-008 Glomerular Hyperfiltration in Fabry Disease","volume":"4","author":"Perretta","year":"2019","journal-title":"Kidney Int. Rep."},{"key":"ref_118","first-page":"318","article-title":"Parapelvic cysts, a distinguishing feature of renal Fabry disease","volume":"33","author":"Pisani","year":"2018","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc.-Eur. Ren. Assoc."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s40620-022-01375-0","article-title":"Parapelvic Cysts: An Imaging Marker of Kidney Disease Potentially Leading to the Diagnosis of Treatable Rare Genetic Disorders? A Narrative Review of the Literature","volume":"35","author":"Capuano","year":"2022","journal-title":"J. Nephrol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal Biopsy Findings in Children and Adolescents with Fabry Disease and Minimal Albuminuria","volume":"51","author":"Bostad","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1681\/ASN.2019050497","article-title":"Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss","volume":"31","author":"Najafian","year":"2020","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000507997","article-title":"Mechanisms of Podocyte Detachment, Podocyturia, and Risk of Progression of Glomerulopathies","volume":"6","author":"Trimarchi","year":"2020","journal-title":"Kidney Dis."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Levstek, T., Vujkovac, B., and Trebusak Podkrajsek, K. (2020). Biomarkers of Fabry Nephropathy: Review and Future Perspective. Genes, 11.","DOI":"10.3390\/genes11091091"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/cge.12386","article-title":"The kidney in Fabry\u2019s disease","volume":"86","author":"Pisani","year":"2014","journal-title":"Clin. Genet."},{"key":"ref_125","first-page":"2102","article-title":"Fabry disease: Progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc.-Eur. Ren. Assoc."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1172\/JCI72267","article-title":"Cellular and molecular mechanisms in kidney fibrosis","volume":"124","author":"Duffield","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev-physiol-022516-034227","article-title":"Mechanisms of Renal Fibrosis","volume":"80","author":"Humphreys","year":"2018","journal-title":"Annu. Rev. Physiol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41586-020-2941-1","article-title":"Decoding myofibroblast origins in human kidney fibrosis","volume":"589","author":"Kuppe","year":"2021","journal-title":"Nature"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ymgme.2019.10.010","article-title":"Pathogenesis of Fabry nephropathy: The pathways leading to fibrosis","volume":"129","author":"Rozenfeld","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrneph.2015.215","article-title":"Renal fibrosis in 2015: Understanding the mechanisms of kidney fibrosis","volume":"12","author":"Zhou","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Jeon, Y.J., Jung, N., Park, J.W., Park, H.Y., and Jung, S.C. (2015). Epithelial-Mesenchymal Transition in Kidney Tubular Epithelial Cells Induced by Globotriaosylsphingosine and Globotriaosylceramide. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0136442"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/nm.3901","article-title":"Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease","volume":"21","author":"Grande","year":"2015","journal-title":"Nat. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","article-title":"Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week","volume":"77","author":"Pieroni","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_134","first-page":"53","article-title":"Early cardiac changes in children with anderson-fabry disease","volume":"11","author":"Havranek","year":"2013","journal-title":"JIMD Rep."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/8904_2014_371","article-title":"Innate and Adaptive Immune Response in Fabry Disease","volume":"22","author":"Mauhin","year":"2015","journal-title":"JIMD Reports"},{"key":"ref_136","first-page":"1797","article-title":"Globotriaosylsphingosine actions on human glomerular podocytes: Implications for Fabry nephropathy","volume":"26","author":"Sanz","year":"2011","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc.-Eur. Ren. Assoc."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.jcmg.2018.03.020","article-title":"Proposed Stages of Myocardial Phenotype Development in Fabry Disease","volume":"12","author":"Nordin","year":"2019","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e010171","DOI":"10.1161\/CIRCIMAGING.119.010171","article-title":"Myocardial Edema, Myocyte Injury, and Disease Severity in Fabry Disease","volume":"13","author":"Augusto","year":"2020","journal-title":"Circulation. Cardiovasc. Imaging"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e008424","DOI":"10.1161\/CIRCIMAGING.118.008424","article-title":"Predictors of Clinical Evolution in Prehypertrophic Fabry Disease","volume":"12","author":"Camporeale","year":"2019","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Gatterer, C., Beitzke, D., Sunder-Plassmann, G., Friedl, M., Hohensinner, P., Mann, C., Ponleitner, M., Graf, S., and Lenz, M. (2024). NT-proBNP Reflects Left Ventricular Hypertrophy Rather than Left Ventricular Dilatation or Systolic Dysfunction in Patients with Fabry Disease. J. Clin. Med., 13.","DOI":"10.3390\/jcm13195953"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.humpath.2015.07.017","article-title":"Increased oxidative stress contributes to cardiomyocyte dysfunction and death in patients with Fabry disease cardiomyopathy","volume":"46","author":"Chimenti","year":"2015","journal-title":"Hum. Pathol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.carpath.2009.05.003","article-title":"A detailed pathologic examination of heart tissue from three older patients with Anderson\u2013Fabry disease on enzyme replacement therapy","volume":"19","author":"Sheppard","year":"2010","journal-title":"Cardiovasc. Pathol."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Bosch, M.E., and Kielian, T. (2015). Neuroinflammatory paradigms in lysosomal storage diseases. Front. Neurosci., 9.","DOI":"10.3389\/fnins.2015.00417"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neures.2013.10.004","article-title":"Neuroinflammation: The role and consequences","volume":"79","author":"Lyman","year":"2014","journal-title":"Neurosci. Res."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Par\u00e1, C., Bose, P., and Pshezhetsky, A.V. (2020). Neuropathophysiology of Lysosomal Storage Diseases: Synaptic Dysfunction as a Starting Point for Disease Progression. J. Clin. Med., 9.","DOI":"10.3390\/jcm9030616"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Carnicer-C\u00e1ceres, C., Arranz-Amo, J.A., Cea-Arestin, C., Camprodon-Gomez, M., Moreno-Martinez, D., Lucas-Del-Pozo, S., Molt\u00f3-Abad, M., Tigri-Santi\u00f1a, A., Agraz-Pamplona, I., and Rodriguez-Palomares, J.F. (2021). Biomarkers in Fabry Disease. Implications for Clinical Diagnosis and Follow-up. J. Clin. Med., 10.","DOI":"10.3390\/jcm10081664"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jns.2007.01.053","article-title":"The cerebral vasculopathy of Fabry disease","volume":"257","author":"Moore","year":"2007","journal-title":"J. Neurol. Sci."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Tuttolomondo, A., Baglio, I., Riolo, R., Todaro, F., Parrinello, G., Miceli, S., and Simonetta, I. (2024). Molecular Pathogenesis of Central and Peripheral Nervous System Complications in Anderson\u2013Fabry Disease. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202308.1540.v1"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1161\/ATVBAHA.107.159327","article-title":"Role of smooth muscle cells in the initiation and early progression of atherosclerosis","volume":"28","author":"Doran","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1128\/CMR.17.4.942-964.2004","article-title":"Role of microglia in central nervous system infections","volume":"17","author":"Rock","year":"2004","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.arr.2014.11.003","article-title":"DAMPs and neurodegeneration","volume":"24","author":"Thundyil","year":"2015","journal-title":"Ageing Res. Rev."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/imm.12233","article-title":"Inflammation in neurodegenerative diseases\u2014An update","volume":"142","author":"Amor","year":"2014","journal-title":"Immunology"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/jnnp.70.1.9","article-title":"Prevalence of cerebral white matter lesions in elderly people: A population based magnetic resonance imaging study. The Rotterdam Scan Study","volume":"70","author":"Achten","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"20","DOI":"10.20517\/rdodj.2024.13","article-title":"Neuropathy and pain in Fabry disease","volume":"3","author":"Medala","year":"2024","journal-title":"Rare Dis. Orphan Drugs J."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ymgme.2012.03.010","article-title":"Small fiber neuropathy in Fabry disease","volume":"106","author":"Biegstraaten","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2027852","DOI":"10.1080\/19490976.2022.2027852","article-title":"Fabry disease\u2014A multisystemic disease with gastrointestinal manifestations","volume":"14","author":"Lenders","year":"2022","journal-title":"Gut Microbes"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.sjpain.2017.08.002","article-title":"Targeting cytokines for treatment of neuropathic pain","volume":"17","author":"Hung","year":"2017","journal-title":"Scand. J. Pain"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cell.2009.09.028","article-title":"Cellular and molecular mechanisms of pain","volume":"139","author":"Basbaum","year":"2009","journal-title":"Cell"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrn2533","article-title":"Pathological and protective roles of glia in chronic pain","volume":"10","author":"Milligan","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nri3621","article-title":"Pathological pain and the neuroimmune interface","volume":"14","author":"Grace","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Vanderwall, A.G., and Milligan, E.D. (2019). Cytokines in Pain: Harnessing Endogenous Anti-Inflammatory Signaling for Improved Pain Management. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.03009"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1021\/acsptsci.3c00219","article-title":"Apabetalone (RVX-208): A Potential Epigenetic Therapy for the Treatment of Cardiovascular, Renal, Neurological, Viral, and Cancer Disorders","volume":"7","author":"Dhulkifle","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40256-017-0250-3","article-title":"Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease","volume":"18","author":"Nicholls","year":"2018","journal-title":"Am. J. Cardiovasc. Drugs Drugs Devices Other Interv."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Wiesinger, A.-M., Bigger, B., Giugliani, R., Scarpa, M., Moser, T., Lampe, C., Kampmann, C., and Lagler, F.B. (2022). The Inflammation in the Cytopathology of Patients with Mucopolysaccharidoses- Immunomodulatory Drugs as an Approach to Therapy. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.863667"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/15\/7054\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:14:06Z","timestamp":1760033646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/15\/7054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":164,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["ijms26157054"],"URL":"https:\/\/doi.org\/10.3390\/ijms26157054","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]}}}